StockData
NeuroPace Inc logo

NeuroPace Inc (NPCE) stock

NPCENasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 5/3013% above fair value
$7.56−4.46 (-37.10%)

Close on Nov 13, 2026Market cap $259.49MP/E –Yield 0.00%

Earnings

NeuroPace's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Mar 2, 2027
Q4 FY2026 · estimated, during market hours
Revenue, Q3 FY2026
$23.10M
-15.7% on a year earlier
EPS, Q3 FY2026
-$0.10
-$0.11 a year earlier
Latest guidance
Issued
Nov 12, 2026 · 6 items

Quarterly results

Revenue and earnings per share from each of NeuroPace's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q4 FY2026ended Dec 31, 2026Mar 2, 2027Expected––––
Q3 FY2026ended Sep 30, 2026Nov 12, 2026after the close$23.10M-15.7%-$0.10Release
Q2 FY2026ended Jun 30, 2026Aug 11, 2026during market hours$22.80M-3.0%–Release
Q1 FY2026ended Mar 31, 2026May 12, 2026during market hours$22.10M-1.8%–Release
Q4 FY2025ended Dec 31, 2025Mar 3, 2026during market hours$26.60M+23.7%–Release
Q3 FY2025ended Sep 30, 2025Nov 4, 2025during market hours$27.40M+29.9%-$0.11Release
Q2 FY2025ended Jun 30, 2025Aug 12, 2025during market hours$23.50M+21.8%–Release
Q1 FY2025ended Mar 31, 2025May 13, 2025during market hours$22.50M+24.3%–Release
Q4 FY2024ended Dec 31, 2024Mar 4, 2025during market hours$21.50M+19.4%-$0.18Release
Q3 FY2024ended Sep 30, 2024Nov 12, 2024during market hours$21.10M+28.7%–Release
Q2 FY2024ended Jun 30, 2024Aug 13, 2024during market hours$19.30M+17.0%-$0.26Release
Q1 FY2024ended Mar 31, 2024May 8, 2024during market hours$18.10M+24.8%-$0.32Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

NeuroPace's latest outlook for periods it has not reported yet, compared with what it said before

MetricPeriodGuidanceBeforeChangeGiven
total revenueFY2026$91.00M – $92.00M–NewNov 12, 2026
total revenueFY2026$99.50M – $101.50M$99.00M – $101.00MRaisedAug 11, 2026
GAAP gross marginGAAPFY202681% – 82%–NewMar 3, 2026
non-GAAP gross marginnon-GAAPFY202683% – 83.5%–NewNov 12, 2026
non-GAAP gross marginnon-GAAPFY202682% – 83%81.5% – 82.5%RaisedAug 11, 2026
Adjusted EBITDAnon-GAAPFY2026-$9.50M – -$8.50M–NewNov 12, 2026
Adjusted EBITDAnon-GAAPFY2026-$8.50M – -$7.50M-$9.50M – -$8.50MRaisedAug 11, 2026
expected service revenueFY2026$1.00M–NewNov 12, 2026
full year non-GAAP operating expensesnon-GAAPFY2026$90.00M – $92.00M–ReaffirmedMay 12, 2026
GAAP operating expensesGAAPFY2026$100.00M – $102.00M–NewMar 3, 2026
non-GAAP operating expensesnon-GAAPFY2026$85.00M – $86.00M–NewNov 12, 2026
non-GAAP operating expensesnon-GAAPFY2026$90.00M – $92.00M–ReaffirmedAug 11, 2026
Total non-GAAP operating expensesnon-GAAPFY2026$90.00M – $92.00M–NewMar 3, 2026
underlying RNS growthFY2026+10% – +11%–NewNov 12, 2026
underlying RNS growthFY2026+21% – +23%–NewMay 12, 2026

Guidance vs results

The last range NeuroPace gave before each report, against the figure it then reported. Full years add up the four quarters.

PeriodMetricGuidanceActualResult
Q1 FY2026Revenue$21.00M – $22.00M$22.10MAbove range
FY2025Revenue$97.00M – $98.00M$100.00MΣ4QAbove range
Q1 FY2022Revenue$10.00M – $11.00M$11.40MAbove range

Guidance history

Every forecast NeuroPace put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Nov 12, 2026Adjusted EBITDAFY2026-$9.50M – -$8.50MNew
Nov 12, 2026non-GAAP gross marginFY202683% – 83.5%New
Nov 12, 2026underlying RNS growthFY2026+10% – +11%New
Nov 12, 2026expected service revenueFY2026$1.00MNew
Nov 12, 2026non-GAAP operating expensesFY2026$85.00M – $86.00MNew
Nov 12, 2026total revenueFY2026$91.00M – $92.00MNew
Aug 11, 2026Adjusted EBITDAFY2026-$8.50M – -$7.50MRaised
Aug 11, 2026non-GAAP gross marginFY202682% – 83%Raised
Aug 11, 2026non-GAAP operating expensesFY2026$90.00M – $92.00MReaffirmed
Aug 11, 2026total revenueFY2026$99.50M – $101.50MRaised
May 12, 2026Adjusted EBITDAFY2026-$9.50M – -$8.50MRaised
May 12, 2026full year non-GAAP gross marginFY202681.5% – 82.5%Reaffirmed
May 12, 2026underlying RNS growthFY2026+21% – +23%New
May 12, 2026full year non-GAAP operating expensesFY2026$90.00M – $92.00MReaffirmed
May 12, 2026total revenueFY2026$99.00M – $101.00MRaised
Mar 3, 2026Adjusted EBITDAFY2026-$10.00M – -$9.00MNew
Mar 3, 2026GAAP gross marginFY202681% – 82%New
Mar 3, 2026Non-GAAP gross marginFY202681.5% – 82.5%New
Mar 3, 2026GAAP operating expensesFY2026$100.00M – $102.00MNew
Mar 3, 2026Total non-GAAP operating expensesFY2026$90.00M – $92.00MNew

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases NeuroPace filed with the SEC as exhibits to Form 8-K or 6-K

  1. NeuroPace Reports Third Quarter 2026 Financial Results and Provides Revised Full Year Guidance
    Results
  2. NeuroPace Reports Second Quarter 2026 Financial Results and Raises 2026 Revenue Guidance
    Results
  3. NeuroPace Receives FDA Guidance on PMA Supplement for Indication Expansion into Idiopathic Generalized
    Update
  4. NeuroPace Reports First Quarter 2026 Financial Results and Raises 2026 Revenue Guidance
    Results
  5. NeuroPace Reports Fourth Quarter and Full Year 2025 Financial Results and Reiterates 2026 Outlook
    Results
  6. NeuroPace Reports Third Quarter 2025 Financial Results and Increases 2025 Revenue Guidance
    Results
  7. NeuroPace Reports Second Quarter 2025 Financial Results and Increases 2025 Revenue Guidance
    Results
  8. NeuroPace Announces Strategic CFO Transition
    Update
  9. NeuroPace Secures Up to $75 Million in Debt Financing
    Update
  10. NeuroPace Announces Preliminary Results from One-Year Data in NAUTILUS Study
    Update
  11. NeuroPace Reports First Quarter 2025 Financial Results
    Results
  12. NeuroPace Provides Update on Tariff Status
    Update
  13. NeuroPace Announces Refocusing of Product Portfolio
    Update
  14. NeuroPace Reports Fourth Quarter and Full Year 2024 Financial Results
    Results
  15. NeuroPace Completes Repurchase of 5.3 Million Shares of Its Common Stock from KCK Ltd.
    Update

See a number that looks wrong?